| Report ID | 275630 |
| Drug Identification Number | 02541637 |
| Brand name | QUILLIVANT ER ORAL SUSPENSION |
| Common or Proper name | Methylphenidate Hydrochloride Extended-Release Powder for Oral Suspension |
| Company Name | KYE PHARMACEUTICALS INC. |
| Market Status | MARKETED |
| Active Ingredient(s) | METHYLPHENIDATE HYDROCHLORIDE |
| Strength(s) | 5MG |
| Dosage form(s) | POWDER (EXTENDED RELEASE) |
| Route of administration | ORAL |
| Packaging size | 300 mg, 600 mg, 750 mg and 900 mg/bottle |
| ATC code | N06BA |
| ATC description | PSYCHOSTIMULANTS AND NOOTROPICS |
| Reason for shortage | Delay in shipping of the drug. |
| Anticipated start date | 2026-01-08 |
| Actual start date | 2026-01-08 |
| Estimated end date | 2026-02-18 |
| Actual end date | |
| Shortage status | Actual shortage |
| Updated date | 2026-01-08 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 2233 ARGENTIA ROAD, EAST TOWER, SUITE 302 & 302A MISSISSAUGA, ONTARIO CANADA L5N 2X7 |
| Company contact information |
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v4 | 2026-01-08 | French | Compare |
| v3 | 2026-01-08 | English | Compare |
| v2 | 2026-01-08 | French | Compare |
| v1 | 2026-01-08 | English | Compare |
Showing 1 to 4 of 4